A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors - Crowther, M; Levy, G; Lu, G (Presented at the 56th annual meeting of the American Society of Hematology, 2014)
December 6–9